Skip to main content

Advertisement

Table 1 Clinical features of patients

From: Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

Items Erlotinib Group (N = 108) Gefinitib Group (N = 171) P value
Age, y (%) 0.719
  ≥ 60 45 (41.7%) 75 (43.9%)  
  < 60 63 (58.3%) 96 (56.1%)  
Gender, n (%) 0.343
 Male 53 (49.1%) 74 (43.3%)  
 Female 55 (50.9%) 97 (56.7%)  
Smoking history a, n (%)    0.359
 Never smoking 70 (64.8%) 120 (70.2%)  
 Now/once smoking 38 (35.2%) 51 (29.8%)  
ECOG PS score, n (%) 0.491
 0-1 106 (98.1%) 165 (96.5%)  
 2 2 (1.9%) 6 (3.5%)  
Pathological type, n (%) 1.000
 Adenocarcinoma 98 (90.7%) 156 (91.2%)  
 Non adenocarcinoma 10 (9.3%) 15 (8.8%)  
Cancer stagingb, n (%) 0.088
 Recurrent type c 18 (16.7%) 44 (25.7%)  
 IIIb stage 7 (6.5%) 17 (9.9%)  
IV stage 83 (76.9%) 110 (64.3%)  
Cerebral metastasis before EGFR-TKIs use, n (%) 24 (22.2%) 22 (12.9%) 0.047
Previous treatment of cerebral metastasis, No.
 WBRT + TKI 14 11  
 Surgery + WBRT 2 3 (1)  
 WBRT + SRS 4 5  
 None 4 3  
Cerebral metastasis number before EGFR-TKIs use, n
 1 2 3  
 2-3 4 5  
  ≥ 4 18 14  
  1. a Present smoker was defined as someone who had smoked more than 100 cigarettes in their lifetime but either currently being smoking or stopped smoking less than 1 year ago; former smoker was defined as someone who had smoked more than 100 cigarettes in their lifetime and stopped smoking at least 1 year ago; non-smoker was defined as having either smoked 100 or fewer cigarettes in their lifetime or had never smoked cigarettes
  2. b American Joint Committee on Cancer staging system 7th edition
  3. c Patients with stage I-IIIa NSCLC with systemic recurrence following definitive therapy that included surgical resection or radiotherapy